Georgia Behavioral Health

Spravato® Esketamine Treatment

Discover Relief with Spravato® Esketamine Therapy in Norcross, GA

An FDA-Approved Solution for Treatment-Resistant Depression

Spravato®: A New Path to Mental Health Relief

Spravato® (esketamine) is an innovative, FDA-approved treatment specifically designed for individuals struggling with treatment-resistant depression (TRD). Unlike traditional antidepressants, Spravato® works rapidly to target symptoms, providing hope for those who have not found success with conventional therapies.

Administered in a controlled clinical setting under the supervision of a trained healthcare provider in Norcross, GA, Spravato® is a nasal spray that, combined with oral antidepressants (esketamine), helps restore balance and improve mental health.

Key Benefits of Spravato® Esketamine Therapy:

  • Fast-acting relief for symptoms of treatment-resistant depression.
  • Administered in a safe, monitored environment.
  • Provides hope for individuals who haven’t responded to traditional treatments.

Take the next step in your mental health journey with Georgia Behavioral Health. Our team is here to guide you through the Spravato® treatment process and help you regain control of your life.

Start Your Healing Journey

Contact us today to learn more about Spravato® Esketamine therapy and find out if it’s right for you. 

FAQs About Spravato® Esketamine

What is Spravato®?

Spravato® is an FDA-approved nasal spray containing esketamine, a rapid-acting treatment for individuals with treatment-resistant depression. It is used alongside oral antidepressants to improve mental health.

Spravato® targets specific receptors in the brain associated with mood regulation. By restoring chemical imbalances, it helps alleviate symptoms of depression more quickly than traditional antidepressants.

Esketamine is a derivative of ketamine, specifically developed and FDA-approved for depression treatment. Ketamine, while also effective, is often used off-label for mental health conditions.

Spravato® Esketamine is administered under medical supervision. During the session, patients use the nasal spray in a comfortable, monitored setting and are observed for two hours. Most patients experience noticeable symptom relief after a few sessions.

Common side effects include dizziness, nausea, sedation, and temporary dissociation. These are typically mild and resolve shortly after the session.
Spravato® is FDA-approved for treatment-resistant depression and is an option for individuals who have not responded to multiple traditional antidepressants. A thorough evaluation by a healthcare provider can confirm your eligibility.